---
document_datetime: 2025-07-14 14:19:54
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/waylivra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: waylivra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6738913
conversion_datetime: 2025-12-20 09:21:26.519864
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## WAYLIVRA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 11/07/2025                          |                                             | Annex II                         |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000280220          | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - To provide an updated RMP to change the final due date for a non- interventional PASS Study from Q3 2026 to Q4 2028 following the PRAC PASS protocol amendment assessment report EMA/PASS/0000262889. Annex II has been updated accordingly. Additionally, the MAH has taken the opportunity to update the dates of completion of milestones for WAY4001 PASS and registry in alignment with the updated PASS protocol version 5.0.   |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PASS / EMA/PASS/0000262889 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/06/2025 | Based on the PRAC review of the amended PASS protocol version 5.0 dated 21/02/2025 and in accordance with Article 107o of Directive 2001/83/EC, the PRAC considers that the study is non-interventional and the substantial amendments to the imposed category 2 PASS protocol for Volanesorsen sodium (Waylivra) can be endorsed. It is recommended to amend the Risk Management Plan and Annex II.E of the Product Information of the Marketing Authorisation to reflect the updated milestones currently proposed by the MAH. The MAH is required to submit a variation, via the appropriate regulatory procedure, to update the requirements of the specific obligation as agreed by |

<div style=\"page-break-after: always\"></div>

|                            |     | PRAC.                                                                                                                                                                                                                                                 |
|----------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248465 | - - | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing volanesorsen remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |